511 Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-30.
511 Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 30, 2026. The filing reports $500K sold. Its industry group is Biotechnology. It names Shuguang Zhang (Executive Officer, Director), Yancen Lu (Director), Uwe Sleytr (Director) (SEC Form D, October 30, 2026).
Selling to 511 Therapeutics, Inc.? See who runs it and how to reach them, plus this week's 44 other newly funded companies.
Is this your company?
Sell to companies like 511 Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-30 · the record
Pitching, partnering or investing alongside them? See who really runs and owns 511 Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind 511 Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in October 2026, largest first.
Get an email when 511 Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when 511 Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch 511 Therapeutics, Inc. →Get the full cited report on 511 Therapeutics, Inc.
What the filing shows about 511 Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 511 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives 511 Therapeutics, Inc.'s address as 1770 Massachusetts Avenue, #511, Cambridge, MA 02140.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for 511 Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
511 Therapeutics, Inc. is a registered filer with the SEC (CIK 1946264) and has filed since 2022-10-06. 2 filings are on record, the latest on 2026-10-30.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
511 Therapeutics, Inc.'s Form D of 2026-10-30 names Shuguang Zhang, Yancen Lu, Uwe Sleytr and 1 more as its officers, directors or promoters.
Its new offerings report $550K sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week. The dot is this raise, $500K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Shuguang Zhang is named as Executive Officer and Director on the Form D that 511 Therapeutics, Inc. filed with the SEC on 30 October 2026, one of 4 people that filing names.
Yancen Lu is named as Director on the Form D that 511 Therapeutics, Inc. filed with the SEC on 30 October 2026, one of 4 people that filing names.
Uwe Sleytr is named as Director on the Form D that 511 Therapeutics, Inc. filed with the SEC on 30 October 2026, one of 4 people that filing names.
Andrew Marshall is named as Executive Officer and Director on the Form D that 511 Therapeutics, Inc. filed with the SEC on 30 October 2026, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2026-10-30 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about 511 Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 511 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 511 Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist 511 Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind 511 Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for 511 Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises, week of 2026-10-26 · Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/511-therapeutics-inc-form-d-000003